Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Cannabinoids, particularly cannabidiol (CBD) and tetrahydrocannabinol (THC), have been investigated for their potential role in the management of autoimmune disorders. The scientific rationale is based on the interaction of cannabinoids with the endocannabinoid system (ECS), which plays a modulatory role in immune function. Preclinical studies have shown that cannabinoids can reduce inflammation, modulate T-cell activity, and decrease cytokine production, mechanisms relevant to autoimmune pathologies such as multiple sclerosis (MS), rheumatoid arthritis (RA), and inflammatory bowel diseases (IBD). Some clinical trials—most notably in MS—have demonstrated that cannabinoid-based medications (like Sativex, a THC/CBD oromucosal spray) can reduce spasticity and improve quality of life, though evidence for a direct disease-modifying effect on autoimmunity is limited.

For other autoimmune conditions, human studies are generally small, preliminary, or focused on symptom relief (e.g., pain, spasticity) rather than underlying immune modulation. Systematic reviews and meta-analyses cite moderate evidence for symptomatic benefit in MS, with insufficient evidence for most other autoimmune diseases. The safety profile is generally acceptable at therapeutic doses, though side effects (e.g., dizziness, cognitive changes) are noted. Thus, while cannabinoids are not first-line treatments for autoimmune disorders, their use as adjuncts for symptom management has some scientific support, particularly in MS. Ongoing research is needed to clarify their role in broader autoimmune disease management.

More about Cannabinoids
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by Cannabinoids

Products containing Cannabinoids